Copper to Zinc Ratio in End Stage Renal Disease Patients Outcome

Impact of Copper to Zinc Ratio on Outcome of End Stage Renal Disease Patients

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07109778

Enrollment

150

Registered

2025-08-07

Start date

2025-08-01

Completion date

2026-04-01

Last updated

2025-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Control Condition, ESRD (End Stage Renal Disease)

Brief summary

The goal of this observational clinical trial is to Study the impact of copper to zinc ratio on the outcome of ESRD patients

Detailed description

End-stage renal disease (ESRD) carries high morbidity and mortality due to cardiovascular complications, highlighting the need for ongoing research. Trace elements as copper (Cu), and zinc (Zn), are essential for physiological functions, enzyme activity, metabolism, and immune defense. In ESRD patients, Cu and Zn imbalances, with a higher Cu/Zn ratio are linked to greater cardiovascular problems. The relationship between the Cu/Zn ratio and clinical outcomes in ESRD needs more exploration

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* ESRD patients including those on maintenance HD

Exclusion criteria

* Acute kidney injury or rapidly progressive glomerulonephritis, acute infections or active inflammatory conditions as sepsis and autoimmune diseases, liver cirrhosis (Child-Pugh Class B or C), gastrointestinal disorders as inflammatory bowel disease, malabsorption, history of organ transplantation excluding kidney transplantation who may be included in a separate analysis if sufficient numbers are recruited, receiving total parenteral nutrition, Cu or Zn metabolism disorders as Wilson's disease, vitamin complex supplementation or antioxidants within the past 6 months, recent hospitalization within the past 3 months, recent surgery within 3 months, recent blood transfusion \< 3 months, Pregnancy or lactation, Malignancy.

Design outcomes

Primary

Measure	Time frame	Description
To determine whether an elevated serum Cu/Zn ratio is associated with an increased risk of cardiac complications in chronic hemodialysis patients.	6-8 months	measuring serum Cu/Zn ratio and determining if it is associated with an increased risk of cardiac complications in chronic hemodialysis patients.

Countries

Egypt

Contacts

Primary ContactKerolles Adel Estawrow Saleh, MBChB

Kerolesadel1997@gmail.com01227657867

Outcome results